PPARG and metabolic dysfunction-associated steatotic liver disease: This study identifies stachyose (STA), a natural oligosaccharide, as a novel partial PPARγ agonist with superior therapeutic efficacy over rosiglitazone in non‐alcoholic fatty liver disease (NAFLD).